What is CAMP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CAMP?

P/E (TTM) is n/a and 52-week range is $2.86 to $7.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CAMP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CAMP?

The company profile lists revenue (TTM) near $411M, net income (TTM) near $-2.99B, EPS (TTM) near $-2.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CAMP4 Therapeutics Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 51.9M shares outstanding, ISIN US13463J1016 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

CAMP4 Therapeutics Corp

$CAMP

Health Care · Biotechnology

IR Run Scenarios

$3.77

+1.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2024-10-11. The firm is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Employees

Website

www.camp4tx.com/

IPO

2024-10-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)